Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2

Drug Res (Stuttg) DOI: 10.1055/a-2030-4078ErbB1 and ErbB2 are the most important biological targets in cancer drug
discovery and development of dual inhibitors for the cancer therapy. FDA
approved drugs and Neuropep peptides were used to fit into the ATP binding site
of the tyrosine kinases; ErbB1 and ErbB2 proteins. Cytoscape, iGEMDOCK, HPEPDOCK
and DataWarrior softwares were used to study the role of these agents as
anticancer drugs. Eleven FDA approved drugs and eleven Neuropep peptides showed
the strongest 2D interactions and significant binding energy with the proteins.
Invitro MTT anticancer assay revealed that, the test compounds,
peptide YSFGL and doxorubicin showed significant IC50 value
(µM) of 26.417±0.660 and 7.675±0.278 respectively which
are compared with the lapatinib standard IC50 value (µM) of
2.380±0.357 against A549 cells and IC50 value (µM) of
39.047±0.770 and 8.313±0.435 respectively which are compared
with the lapatinib standard IC50 value (µM) of
3.026±0.180 against MDA-MB-231 cells. [...] Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart,
GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text

Source: Drug Research - April 17, 2023 Category: Drugs & Pharmacology Authors: Patnaik, Sunil Kumar Swaroop, Akey Krishna Naik, Mudavath Ravi Selvaraj, Jubie Chandrasekar, Moola Joghee Nanjan Tags: Original Article Source Type: research